← All Dossiers
Catena Biosciences — Series A
In Conversation Fund: StoryHouse Fund II
Dossier generated 2026-05-27 by /deal-dossier  ·  Deal record: recJ8T25Ly8wenjpK  ·  Source: Airtable appjxAR3LPe3fkHOp

One-Liner & Thesis

Catena Biosciences — Biotech, Biotechnology. Catena Biosciences operates in Biotech, Biotechnology; this dossier captures the Series A we participated in.

via StoryHouse Fund II.

Deal Box

Fund
StoryHouse Fund II
Funding Round
Series A

Company Snapshot

Sector
Biotech, Biotechnology
Location
LA, California
Headcount
2
Year Founded
2020-01-01
Total Raised
$8.1M
Website
www.catenabiosciences.com
Status
Private

Founders

Saurabh Johri
Founder/team member at Catena Biosciences.
Jennifer Doudna
Founder/team member at Catena Biosciences.
Marco Lobba
After Pomona, worked at Anresco Laboratories (ended as Quality Manager). PhD at UC Berkeley (Francis/Doudna) focused on CRISPR protein modification and delivery. Incorporated Catena in 2020.

Latest Meeting Notes

2026-05-22 — Deal Call Notes - 2026-05-22

On Fri, May 22, 2026 at 11:28 Miles Bird [miles.t.bird@gmail.com](mailto:miles.t.bird@gmail.com) wrote: > RAW NOTES: > > Good update from Marco during dinner. > > According to Marco, while the deal is not yet closed, he feels more > confident because one of his advisors, Ron, is giving him an inside > perspective on the process, as he is in all…

Source: Meeting Notes rec90AOFblGybtyg0

2026-03-09 — Deal Call Notes - 2026-03-09

RAW NOTES: 1. Jennifer Doudna / Event with StoryHouse + Baker Labs • Marco said Jennifer Doudna’s engagement with the company has been lower recently, largely because their current work isn’t directly focused on the CRISPR side of the field. • He’s had mixed success getting her involved in external events. • However, she’s increasingly inte…

Source: Meeting Notes recsW4izpTmObHptZ